Nanomedicine approaches for sirolimus delivery: a review of pharmaceutical properties and preclinical studies

References

• Sehgal SN, Baker H, Vezina C. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot (Tokyo). 1975;28:727–732.
   PubMed Web of Science ®Google Scholar
• Park SR, Yoo YJ, Ban YH, et al. Biosynthesis of rapamycin and its regulation: past achievements and recent progress. J Antibiot (Tokyo). 2010;63:434–441.
   PubMed Web of Science ®Google Scholar
• Sehgal SN. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc. 2003;35:7s–14s.
   PubMed Web of Science ®Google Scholar
• Dowling RJ, Topisirovic I, Fonseca BD, et al. Dissecting the role of mTOR: lessons from mTOR inhibitors. Biochim Biophys Acta. 2010;1804:433–439.
   PubMed Web of Science ®Google Scholar
• Baretic D, Williams RL. The structural basis for mTOR function. Semin Cell Dev Biol. 2014;36:91–101.
   PubMed Web of Science ®Google Scholar
• MacDonald A, Scarola J, Burke JT, et al. Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. Clin Ther. 2000;22 Suppl B:B101–B121.
   PubMed Web of Science ®Google Scholar
• Mahalati K, Kahan BD. Clinical pharmacokinetics of sirolimus. Clin Pharmacokinet. 2001;40:573–585.
   PubMed Web of Science ®Google Scholar
• Picard N, Djebli N, Sauvage FL, et al. Metabolism of sirolimus in the presence or absence of cyclosporine by genotyped human liver microsomes and recombinant cytochromes P450 3A4 and 3A5. Drug Metab Dispos. 2007;35:350–355.
   PubMed Web of Science ®Google Scholar
• Shihab F, Christians U, Smith L, et al. Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes. Transpl Immunol. 2014;31:22–32.
   PubMed Web of Science ®Google Scholar
• Augustine JJ, Bodziak KA, Hricik DE. Use of sirolimus in solid organ transplantation. Drugs. 2007;67:369–391.
   PubMed Web of Science ®Google Scholar
• Cheng-Lai A, Frishman WH. Sirolimus-eluting coronary stents: novel devices for the management of coronary artery disease. Am J Ther. 2004;11:218–228.
   PubMedGoogle Scholar
• Piscione F, Piccolo R, Cassese S, et al. Clinical impact of sirolimus-eluting stent in ST-segment elevation myocardial infarction: a meta-analysis of randomized clinical trials. Catheter Cardiovasc Interv. 2009;74:323–332.
   PubMed Web of Science ®Google Scholar
• Hartford CM, Ratain MJ. Rapamycin: something old, something new, sometimes borrowed and now renewed. Clin Pharmacol Ther. 2007;82:381–388.
   PubMed Web of Science ®Google Scholar
• Paghdal KV, Schwartz RA. Sirolimus (rapamycin): from the soil of Easter Island to a bright future. J Am Acad Dermatol. 2007;57:1046–1050.
   PubMed Web of Science ®Google Scholar
• Li J, Kim SG, Blenis J. Rapamycin: one drug, many effects. Cell Metab. 2014;19:373–379.
   PubMed Web of Science ®Google Scholar
• Cutler C, Antin JH. Sirolimus for GVHD prophylaxis in allogeneic stem cell transplantation. Bone Marrow Transplant. 2004;34:471–476.
   PubMed Web of Science ®Google Scholar
• Bride KL, Vincent T, Smith-Whitley K, et al. Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. Blood. 2016;127:17–28.
   PubMed Web of Science ®Google Scholar
• Ormerod AD, Shah SA, Copeland P, et al. Treatment of psoriasis with topical sirolimus: preclinical development and a randomized, double-blind trial. Br J Dermatol. 2005;152:758–764.
   PubMed Web of Science ®Google Scholar
• Heredia A, Amoroso A, Davis C, et al. Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV beta-chemokines: an approach to suppress R5 strains of HIV-1. Proc Natl Acad Sci USA. 2003;100:10411–10416.
   PubMed Web of Science ®Google Scholar
• Bove J, Martinez-Vicente M, Vila M. Fighting neurodegeneration with rapamycin: mechanistic insights. Nat Rev Neurosci. 2011;12:437–452.
   PubMed Web of Science ®Google Scholar
• Keogh A, Richardson M, Ruygrok P, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation. 2004;110:2694–2700.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Merrill PT, Clark WL, et al. Intravitreal sirolimus for noninfectious uveitis: a phase III sirolimus study assessing double-masKed uveitis TReAtment (SAKURA). Ophthalmology. 2016;123:2413–2423.
   PubMed Web of Science ®Google Scholar
• Pleyer U, Thurau SR. Sirolimus for the treatment of noninfectious uveitis. Expert Opin Pharmacother. 2016;17:127–135.
   PubMed Web of Science ®Google Scholar
• Stallone G, Infante B, Grandaliano G, et al. Kaposi's sarcoma and mTOR: a crossroad between viral infection neoangiogenesis and immunosuppression. Transpl Int. 2008;21:825–832.
   PubMed Web of Science ®Google Scholar
• Campbell SB, Walker R, Tai SS, et al. Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer. Am J Transplant. 2012;12:1146–1156.
   PubMed Web of Science ®Google Scholar
• Um SH, Frigerio F, Watanabe M, et al. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature. 2004;431:200–205.
   PubMed Web of Science ®Google Scholar
• Ong PS, Wang LZ, Dai X, et al. Judicious toggling of mTOR activity to combat insulin resistance and cancer: current evidence and perspectives. Front Pharmacol. 2016;7:395.
   PubMed Web of Science ®Google Scholar
• Kim EJ, Jeong JH, Bae S, et al. mTOR inhibitors radiosensitize PTEN-deficient non-small-cell lung cancer cells harboring an EGFR activating mutation by inducing autophagy. J Cell Biochem. 2013;114:1248–1256.
   PubMed Web of Science ®Google Scholar
• Nagata Y, Takahashi A, Ohnishi K, et al. Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status. Int J Oncol. 2010;37:1001–1010.
   PubMed Web of Science ®Google Scholar
• Shinohara ET, Maity A, Jha N, et al. Sirolimus as a potential radiosensitizer in squamous cell cancer of the head and neck. Head Neck. 2009;31:406–411.
   PubMed Web of Science ®Google Scholar
• Moes DJ, Guchelaar HJ, de Fijter JW. Sirolimus and everolimus in kidney transplantation. Drug Discov Today. 2015;20:1243–1249.
   PubMed Web of Science ®Google Scholar
• Simamora P, Alvarez JM, Yalkowsky SH. Solubilization of rapamycin. Int J Pharm. 2001;213:25–29.
   PubMed Web of Science ®Google Scholar
• Yanez JA, Forrest ML, Ohgami Y, et al. Pharmacometrics and delivery of novel nanoformulated PEG-b-poly(epsilon-caprolactone) micelles of rapamycin. Cancer Chemother Pharmacol. 2008;61:133–144.
   PubMed Web of Science ®Google Scholar
• Pathak K, Raghuvanshi S. Oral bioavailability: issues and solutions via nanoformulations. Clin Pharmacokinet. 2015;54:325–357.
   PubMed Web of Science ®Google Scholar
• Chen H, Khemtong C, Yang X, et al. Nanonization strategies for poorly water-soluble drugs. Drug Discov Today. 2011;16:354–360.
   PubMed Web of Science ®Google Scholar
• Aberoumandi SM, Mohammadhosseini M, Abasi E, et al. An update on applications of nanostructured drug delivery systems in cancer therapy: a review. Artif Cells Nanomed Biotechnol. 2017;45:1–11.
   PubMed Web of Science ®Google Scholar
• Panahi Y, Farshbaf M, Mohammadhosseini M, et al. Recent advances on liposomal nanoparticles: synthesis, characterization and biomedical applications. Artif Cells Nanomed Biotechnol. 2017;45:788–799.
   PubMed Web of Science ®Google Scholar
• Daraee H, Etemadi A, Kouhi M, et al. Application of liposomes in medicine and drug delivery. Artif Cells Nanomed Biotechnol. 2016;44:381–391.
   PubMed Web of Science ®Google Scholar
• Alavi S, Haeri A, Dadashzadeh S. Utilization of chitosan-caged liposomes to push the boundaries of therapeutic delivery. Carbohydr Polym. 2017;157:991–1012.
   PubMed Web of Science ®Google Scholar
• Haeri A, Sadeghian S, Rabbani S, et al. PEGylated estradiol benzoate liposomes as a potential local vascular delivery system for treatment of restenosis. J Microencapsul. 2012;29:83–94.
   PubMed Web of Science ®Google Scholar
• Maeda H. Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting. Proc Jpn Acad Ser B Phys Biol Sci. 2012;88:53–71.
   PubMed Web of Science ®Google Scholar
• Suk JS, Xu Q, Kim N, et al. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev. 2016;99:28–51.
   PubMed Web of Science ®Google Scholar
• Marques-Gallego P, de Kroon AI. Ligation strategies for targeting liposomal nanocarriers. Biomed Res Int. 2014;2014:129458.
   PubMed Web of Science ®Google Scholar
• Haeri A, Sadeghian S, Rabbani S, et al. Use of remote film loading methodology to entrap sirolimus into liposomes: preparation, characterization and in vivo efficacy for treatment of restenosis. Int J Pharm. 2011;414:16–27.
   PubMed Web of Science ®Google Scholar
• Haeri A, Sadeghian S, Rabbani S, et al. Physicochemical characteristics of liposomes are decisive for their antirestenosis efficacy following local delivery. Nanomedicine (Lond). 2017;12:131–145.
   PubMed Web of Science ®Google Scholar
• Haeri A, Sadeghian S, Rabbani S, et al. Effective attenuation of vascular restenosis following local delivery of chitosan decorated sirolimus liposomes. Carbohydr Polym. 2017;157:1461–1469.
   PubMed Web of Science ®Google Scholar
• Pang X, Wang J, Tan X, et al. Dual-modal imaging-guided theranostic nanocarriers based on indocyanine green and mTOR inhibitor rapamycin. ACS Appl Mater Interfaces. 2016;8:13819–13829.
   PubMed Web of Science ®Google Scholar
• Ghanbarzadeh S, Khorrami A, Mohamed Khosroshahi L, et al. Fusogenic pH sensitive liposomal formulation for rapamycin: improvement of antiproliferative effect. Pharm Biol. 2014;52:848–854.
   PubMed Web of Science ®Google Scholar
• Ghanbarzadeh S, Arami S, Pourmoazzen Z, et al. Improvement of the antiproliferative effect of rapamycin on tumor cell lines by poly (monomethylitaconate)-based pH-sensitive, plasma stable liposomes. Colloids Surf B Biointerfaces. 2014;115:323–330.
   PubMed Web of Science ®Google Scholar
• Alemdar AY, Sadi D, McAlister VC, et al. Liposomal formulations of tacrolimus and rapamycin increase graft survival and fiber outgrowth of dopaminergic grafts. Cell Transplant. 2004;13:263–271.
   PubMed Web of Science ®Google Scholar
• Rouf MA, Vural I, Renoir JM, et al. Development and characterization of liposomal formulations for rapamycin delivery and investigation of their antiproliferative effect on MCF7 cells. J Liposome Res. 2009;19:322–331.
   PubMed Web of Science ®Google Scholar
• Eloy JO, Petrilli R, Topan JF, et al. Co-loaded paclitaxel/rapamycin liposomes: development, characterization and in vitro and in vivo evaluation for breast cancer therapy. Colloids Surf B Biointerfaces. 2016;141:74–82.
   PubMed Web of Science ®Google Scholar
• Haeri A, Sadeghian S, Rabbani S, et al. Sirolimus-loaded stealth colloidal systems attenuate neointimal hyperplasia after balloon injury: a comparison of phospholipid micelles and liposomes. Int J Pharm. 2013;455:320–330.
   PubMed Web of Science ®Google Scholar
• Zhang W, Sun Y, Li Y, et al. Preparation and influencing factors of sirolimus liposome by supercritical fluid. Artif Cells Blood Substit Immobil Biotechnol. 2012;40:62–65.
   PubMed Web of Science ®Google Scholar
• Buech G, Bertelmann E, Pleyer U, et al. Formulation of sirolimus eye drops and corneal permeation studies. J Ocul Pharmacol Ther. 2007;23:292–303.
   PubMed Web of Science ®Google Scholar
• Linares-Alba MA, Gomez-Guajardo MB, Fonzar JF, et al. Preformulation studies of a liposomal formulation containing sirolimus for the treatment of dry eye disease. J Ocul Pharmacol Ther. 2016;32:11–22.
   PubMed Web of Science ®Google Scholar
• Narvekar M, Xue HY, Eoh JY, et al. Nanocarrier for poorly water-soluble anticancer drugs–barriers of translation and solutions. AAPS PharmSciTech. 2014;15:822–833.
   PubMed Web of Science ®Google Scholar
• Lai P, Daear W, Lobenberg R, et al. Overview of the preparation of organic polymeric nanoparticles for drug delivery based on gelatine, chitosan, poly(d,l-lactide-co-glycolic acid) and polyalkylcyanoacrylate. Colloids Surf B Biointerfaces. 2014;118:154–163.
   PubMed Web of Science ®Google Scholar
• Afsharzadeh M, Hashemi M, Mokhtarzadeh A, et al. Recent advances in co-delivery systems based on polymeric nanoparticle for cancer treatment. Artif Cells Nanomed Biotechnol. 2017. DOI:https://doi.org/10.1080/21691401.2017.1376675
   PubMed Web of Science ®Google Scholar
• Frank LA, Contri RV, Beck RC, et al. Improving drug biological effects by encapsulation into polymeric nanocapsules. Wires Nanomed Nanobiotechnol. 2015;7:623–639.
   PubMed Web of Science ®Google Scholar
• Vauthier C, Bouchemal K. Methods for the preparation and manufacture of polymeric nanoparticles. Pharm Res. 2009;26:1025–1058.
   PubMed Web of Science ®Google Scholar
• Shi X, Chen G, Guo LW, et al. Periadventitial application of rapamycin-loaded nanoparticles produces sustained inhibition of vascular restenosis. PLoS One. 2014;9:e89227.
   PubMed Web of Science ®Google Scholar
• Katiyar SS, Muntimadugu E, Rafeeqi TA, et al. Co-delivery of rapamycin- and piperine-loaded polymeric nanoparticles for breast cancer treatment. Drug Deliv. 2016;23:2608–2616.
   PubMed Web of Science ®Google Scholar
• Acharya S, Dilnawaz F, Sahoo SK. Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy. Biomaterials. 2009;30:5737–5750.
   PubMed Web of Science ®Google Scholar
• Zou J, Zhang X, Yang H, et al. Rapamycin-loaded nanoparticles for inhibition of neointimal hyperplasia in experimental vein grafts. Ann Vasc Surg. 2011;25:538–546.
   PubMed Web of Science ®Google Scholar
• Das S, Haddadi A, Veniamin S, et al. Delivery of rapamycin-loaded nanoparticle down regulates ICAM-1 expression and maintains an immunosuppressive profile in human CD34+ progenitor-derived dendritic cells. J Biomed Mater Res A. 2008;85:983–992.
   PubMed Web of Science ®Google Scholar
• Haddadi A, Elamanchili P, Lavasanifar A, et al. Delivery of rapamycin by PLGA nanoparticles enhances its suppressive activity on dendritic cells. J Biomed Mater Res A. 2008;84:885–898.
   PubMed Web of Science ®Google Scholar
• Moeller S, Kegler R, Sternberg K, et al. Influence of sirolimus-loaded nanoparticles on physiological functions of native human polymorphonuclear neutrophils. Nanomedicine. 2012;8:1293–1300.
   PubMed Web of Science ®Google Scholar
• Zago AC, Raudales JC, Attizzani G, et al. Local delivery of sirolimus nanoparticles for the treatment of in-stent restenosis. Cathet Cardiovasc Intervent. 2013;81:E124–E129.
   PubMed Web of Science ®Google Scholar
• Yuan XB, Yuan YB, Jiang W, et al. Preparation of rapamycin-loaded chitosan/PLA nanoparticles for immunosuppression in corneal transplantation. Int J Pharm. 2008;349:241–248.
   PubMed Web of Science ®Google Scholar
• Shah M, Edman MC, Janga SR, et al. A rapamycin-binding protein polymer nanoparticle shows potent therapeutic activity in suppressing autoimmune dacryoadenitis in a mouse model of Sjogren’s syndrome. J Control Release. 2013;171:269–279.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Zhang T, Duan S, et al. CD44-tropic polymeric nanocarrier for breast cancer targeted rapamycin chemotherapy. Nanomedicine. 2014;10:1221–1230.
   PubMed Web of Science ®Google Scholar
• Bisht S, Feldmann G, Koorstra JB, et al. In vivo characterization of a polymeric nanoparticle platform with potential oral drug delivery capabilities. Mol Cancer Ther. 2008;7:3878–3888.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Xu L, Chen H, et al. Rapamycin-loaded poly(epsilon-caprolactone)-poly(ethylene glycol)-poly(epsilon-caprolactone) nanoparticles: preparation, characterization and potential application in corneal transplantation. J Pharm Pharmacol. 2014;66:557–563.
   PubMed Web of Science ®Google Scholar
• Lu XY, Li MC, Zhu XL, et al. Microbial synthesized biodegradable PHBHHxPEG hybrid copolymer as an efficient intracellular delivery nanocarrier for kinase inhibitor. BMC Biotechnol. 2014;14:4.
   PubMed Web of Science ®Google Scholar
• Reddy MK, Vasir JK, Sahoo SK, et al. Inhibition of apoptosis through localized delivery of rapamycin-loaded nanoparticles prevented neointimal hyperplasia and reendothelialized injured artery. Circ Cardiovasc Interv. 2008;1:209–216.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Huang Y, Li S. Polymeric micelles: nanocarriers for cancer-targeted drug delivery. AAPS PharmSciTech. 2014;15:862–871.
   PubMed Web of Science ®Google Scholar
• Oba M. Study on development of polymeric micellar gene carrier and evaluation of its functionality. Biol Pharm Bull. 2013;36:1045–1051.
   PubMed Web of Science ®Google Scholar
• Jones MC. Thinking outside the ‘block’: alternative polymer compositions for micellar drug delivery. Curr Top Med Chem. 2015;15:2254–2266.
   PubMed Web of Science ®Google Scholar
• Shin HC, Alani AW, Cho H, et al. A 3-in-1 polymeric micelle nanocontainer for poorly water-soluble drugs. Mol Pharm. 2011;8:1257–1265.
   PubMed Web of Science ®Google Scholar
• Hasenstein JR, Shin HC, Kasmerchak K, et al. Antitumor activity of Triolimus: a novel multidrug-loaded micelle containing Paclitaxel, Rapamycin, and 17-AAG. Mol Cancer Ther. 2012;11:2233–2242.
   PubMed Web of Science ®Google Scholar
• Shin HC, Cho H, Lai TC, et al. Pharmacokinetic study of 3-in-1 poly(ethylene glycol)-block-poly(D, L-lactic acid) micelles carrying paclitaxel, 17-allylamino-17-demethoxygeldanamycin, and rapamycin. J Control Release. 2012;163:93–99.
   PubMed Web of Science ®Google Scholar
• Zeng S, Xiong MP. Trilayer micelles for combination delivery of rapamycin and siRNA targeting Y-box binding protein-1 (siYB-1). Biomaterials. 2013;34:6882–6892.
   PubMed Web of Science ®Google Scholar
• Kim MS, Kim JS, Cho WK, et al. Enhanced solubility and oral absorption of sirolimus using D-alpha-tocopheryl polyethylene glycol succinate micelles. Artif Cells Nanomed Biotechnol. 2013;41:85–91.
   PubMed Web of Science ®Google Scholar
• Tian W, Liu J, Guo Y, et al. Self-assembled micelles of amphiphilic PEGylated rapamycin for loading paclitaxel and resisting multidrug resistant cancer cellsdaggerElectronic supplementary information (ESI) available: chemicals and reagents, detailed experimental procedures for materials synthesis, characterization, cellular evaluations and supporting figures and tables. J Mater Chem B Mater Biol Med. 2015;3:1204–1207.
   PubMed Web of Science ®Google Scholar
• Dane KY, Nembrini C, Tomei AA, et al. Nano-sized drug-loaded micelles deliver payload to lymph node immune cells and prolong allograft survival. J Control Release. 2011;156:154–160.
   PubMed Web of Science ®Google Scholar
• O'Neil CP, van der Vlies AJ, Velluto D, et al. Extracellular matrix binding mixed micelles for drug delivery applications. J Control Release. 2009;137:146–151.
   PubMed Web of Science ®Google Scholar
• Nadig SN, Dixit SK, Levey N, et al. Immunosuppressive nano-therapeutic micelles downregulate endothelial cell inflammation and immunogenicity. RSC Adv. 2015;5:43552–43562.
   PubMed Web of Science ®Google Scholar
• Elsaid N, Somavarapu S, Jackson TL. Cholesterol-poly(ethylene) glycol nanocarriers for the transscleral delivery of sirolimus. Exp Eye Res. 2014;121:121–129.
   PubMed Web of Science ®Google Scholar
• Elsaid N, Jackson TL, Gunic M, et al. Positively charged amphiphilic chitosan derivative for the transscleral delivery of rapamycin. Invest Ophthalmol Vis Sci. 2012;53:8105–8111.
   PubMed Web of Science ®Google Scholar
• Lu W, Li F, Mahato RI. Poly(ethylene glycol)-block-poly(2-methyl-2-benzoxycarbonyl-propylene carbonate) micelles for rapamycin delivery: in vitro characterization and biodistribution. J Pharm Sci. 2011;100:2418–2429.
   PubMed Web of Science ®Google Scholar
• Khondee S, Rabinsky EF, Owens SR, et al. Targeted therapy of colorectal neoplasia with rapamycin in peptide-labeled pegylated octadecyl lithocholate micelles. J Control Release. 2015;199:114–121.
   PubMed Web of Science ®Google Scholar
• Leone F, Cavalli R. Drug nanosuspensions: a ZIP tool between traditional and innovative pharmaceutical formulations. Expert Opin Drug Deliv. 2015;12:1607–1625.
   PubMed Web of Science ®Google Scholar
• Gao L, Liu G, Ma J, et al. Drug nanocrystals: in vivo performances. J Control Release. 2012;160:418–430.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Du J, Wang L, et al. State of the art of nanocrystals technology for delivery of poorly soluble drugs. J Nanopart Res. 2016;18:257.
   Web of Science ®Google Scholar
• Junghanns JU, Muller RH. Nanocrystal technology, drug delivery and clinical applications. Int J Nanomedicine. 2008;3:295–309.
   PubMed Web of Science ®Google Scholar
• Dou Y, Guo J, Chen Y, et al. Sustained delivery by a cyclodextrin material-based nanocarrier potentiates antiatherosclerotic activity of rapamycin via selectively inhibiting mTORC1 in mice. J Control Release. 2016;235:48–62.
   PubMed Web of Science ®Google Scholar
• Ghanbarzadeh S, Khorrami A, Pourmoazzen Z, et al. Plasma stable, pH-sensitive non-ionic surfactant vesicles simultaneously enhance antiproliferative effect and selectivity of Sirolimus. Pharm Dev Technol. 2015;20:279–287.
   PubMed Web of Science ®Google Scholar
• Dilnawaz F, Singh A, Mohanty C, et al. Dual drug loaded superparamagnetic iron oxide nanoparticles for targeted cancer therapy. Biomaterials. 2010;31:3694–3706.
   PubMed Web of Science ®Google Scholar
• Liu Q, Zhang J, Sun W, et al. Delivering hydrophilic and hydrophobic chemotherapeutics simultaneously by magnetic mesoporous silica nanoparticles to inhibit cancer cells. Int J Nanomedicine. 2012;7:999–1013.
   PubMed Web of Science ®Google Scholar
• Bibee KP, Cheng YJ, Ching JK, et al. Rapamycin nanoparticles target defective autophagy in muscular dystrophy to enhance both strength and cardiac function. FASEB J. 2014;28:2047–2061.
   PubMed Web of Science ®Google Scholar
• Cho W, Kim MS, Kim JS, et al. Optimized formulation of solid self-microemulsifying sirolimus delivery systems. Int J Nanomedicine. 2013;8:1673–1682.
   PubMed Web of Science ®Google Scholar
• Gasper WJ, Jimenez CA, Walker J, et al. Adventitial nab-rapamycin injection reduces porcine femoral artery luminal stenosis induced by balloon angioplasty via inhibition of medial proliferation and adventitial inflammation. Circ Cardiovasc Interv. 2013;6:701–709.
   PubMed Web of Science ®Google Scholar
• Kim MS, Kim JS, Park HJ, et al. Enhanced bioavailability of sirolimus via preparation of solid dispersion nanoparticles using a supercritical antisolvent process. Int J Nanomedicine. 2011;6:2997–3009.
   PubMed Web of Science ®Google Scholar
• Solymosi T, Angi R, Basa DO, et al. Sirolimus formulation with improved pharmacokinetic properties produced by a continuous flow method. Eur J Pharm Biopharm. 2015;94:135–140.
   PubMed Web of Science ®Google Scholar
• Sobhani H, Tarighi P, Ostad SN, et al. Formulation development and toxicity assessment of triacetin mediated nanoemulsions as novel delivery systems for rapamycin. Iran J Pharm Res. 2015;14(Suppl):3–21.
   Web of Science ®Google Scholar
• Wang J, Guo F, Yu M, et al. Rapamycin/DiR loaded lipid-polyaniline nanoparticles for dual-modal imaging guided enhanced photothermal and antiangiogenic combination therapy. J Control Release. 2016;237:23–34.
   PubMed Web of Science ®Google Scholar
• Visweswaran GR, Gholizadeh S, Ruiters MH, et al. Targeting rapamycin to podocytes using a vascular cell adhesion molecule-1 (VCAM-1)-harnessed SAINT-based lipid carrier system. PLoS One. 2015;10:e0138870.
   PubMed Web of Science ®Google Scholar